<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38318183</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals.</ArticleTitle><Pagination><StartPage>1348041</StartPage><MedlinePgn>1348041</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1348041</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1348041</ELocationID><Abstract><AbstractText Label="BACKGROUND">Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to post-acute sequelae of SARS-CoV-2 (PASC) that can persist for weeks to years following initial viral infection. Clinical manifestations of PASC are heterogeneous and often involve multiple organs. While many hypotheses have been made on the mechanisms of PASC and its associated symptoms, the acute biological drivers of PASC are still unknown.</AbstractText><AbstractText Label="METHODS">We enrolled 494 patients with COVID-19 at their initial presentation to a hospital or clinic and followed them longitudinally to determine their development of PASC. From 341 patients, we conducted multi-omic profiling on peripheral blood samples collected shortly after study enrollment to investigate early immune signatures associated with the development of PASC.</AbstractText><AbstractText Label="RESULTS">During the first week of COVID-19, we observed a large number of differences in the immune profile of individuals who were hospitalized for COVID-19 compared to those individuals with COVID-19 who were not hospitalized. Differences between individuals who did or did not later develop PASC were, in comparison, more limited, but included significant differences in autoantibodies and in epigenetic and transcriptional signatures in double-negative 1 B cells, in particular.</AbstractText><AbstractText Label="CONCLUSIONS">We found that early immune indicators of incident PASC were nuanced, with significant molecular signals manifesting predominantly in double-negative B cells, compared with the robust differences associated with hospitalization during acute COVID-19. The emerging acute differences in B cell phenotypes, especially in double-negative 1 B cells, in PASC patients highlight a potentially important role of these cells in the development of PASC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Leung, Wu, Kheradpour, Chen, Drake, Tong, Ridaura, Zisser, Conrad, Hudson, Allen, Welberry, Parsy-Kowalska, Macdonald, Tapson, Moy, deFilippi, Rosas, Basit, Krishnan, Parthasarathy, Prabhakar, Salvatore and Kim.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Jacqueline M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Michelle J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kheradpour</LastName><ForeName>Pouya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drake</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ridaura</LastName><ForeName>Vanessa K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zisser</LastName><ForeName>Howard C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Providence Little Company of Mary Medical Center Torrance, Torrance, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Oncimmune Limited, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Oncimmune Limited, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welberry</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Oncimmune Limited, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parsy-Kowalska</LastName><ForeName>Celine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Oncimmune Limited, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macdonald</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Oncimmune Limited, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapson</LastName><ForeName>Victor F</ForeName><Initials>VF</Initials><AffiliationInfo><Affiliation>Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moy</LastName><ForeName>James N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>deFilippi</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Inova Schar Heart and Vascular, Falls Church, VA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosas</LastName><ForeName>Ivan O</ForeName><Initials>IO</Initials><AffiliationInfo><Affiliation>Department of Medicine, Baylor College of Medicine, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basit</LastName><ForeName>Mujeeb</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Jerry A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Breathe Chicago Center, University of Illinois Chicago, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parthasarathy</LastName><ForeName>Sairam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care &amp; Sleep Medicine, University of Arizona, Tucson, AZ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhakar</LastName><ForeName>Bellur S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Illinois - College of Medicine, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvatore</LastName><ForeName>Mirella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine and Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">autoantibody</Keyword><Keyword MajorTopicYN="N">double-negative B cells</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>JL, MW, PK, CC, KD, GT, and CK maintain equity ownership and employment at Verily Life Sciences. NH, JA, CW, CP-K, and IM were employed at Oncimmune Limited. SP reports personal fees from Jazz Pharmaceuticals, Inc., and UpToDate, Inc., and grants from Philips, Inc., Sommetrics, Inc., and Regeneron. CD serves on advisory boards for Abbott Diagnostics, Ortho/Quidel Diagnostics, and Roche Diagnostics. JK receives research funding from Regeneron. JK has also provided consulting for GlaxoSmithKline, AstraZeneca, CereVu Medical, Propeller/ResMed, and BData, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38318183</ArticleId><ArticleId IdType="pmc">PMC10838987</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1348041</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Silk BJ, Scobie HM, Duck WM, Palmer T, Ahmad FB, Binder AM, et al. . COVID-19 surveillance after expiration of the public health emergency declaration - United States, May 11, 2023. MMWR Morb Mortal Wkly Rep (2023) 72:523&#x2013;8. doi: 10.15585/mmwr.mm7219e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7219e1</ArticleId><ArticleId IdType="pmc">PMC10208372</ArticleId><ArticleId IdType="pubmed">37167154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad FB, Cisewski JA, Xu J, Anderson RN. Provisional mortality data - United States, 2022. MMWR Morb Mortal Wkly Rep (2023) 72:488&#x2013;92. doi: 10.15585/mmwr.mm7218a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7218a3</ArticleId><ArticleId IdType="pmc">PMC10168603</ArticleId><ArticleId IdType="pubmed">37141156</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med (2023) 29:2347&#x2013;57. doi: 10.1038/s41591-023-02521-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02521-2</ArticleId><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. . Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA (2023) 329:1934&#x2013;46. doi: 10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol (2023) 21:133&#x2013;46. doi: 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell (2022) 185:881&#x2013;95.e20. doi: 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol (2022) 43:268&#x2013;70. doi: 10.1016/j.it.2022.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol (2022) 23:210&#x2013;6. doi: 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, et al. . Persistence of SARS CoV-2 S1 protein in CD16+ Monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol (2021) 12:746021. doi: 10.3389/fimmu.2021.746021</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, et al. . Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep (2021) 36:109518. doi: 10.1016/j.celrep.2021.109518</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, et al. . Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol (2021) 6:eabk1741. doi: 10.1126/sciimmunol.abk1741</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abk1741</ArticleId><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, Haja Mohideen SM, et al. . A dynamic immune response shapes COVID-19 progression. Cell Host Microbe (2020) 27:879&#x2013;82.e2. doi: 10.1016/j.chom.2020.03.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.03.021</ArticleId><ArticleId IdType="pmc">PMC7192089</ArticleId><ArticleId IdType="pubmed">32359396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk AJ, Rustagi A, Zhao NQ, Roque J, Mart&#xed;nez-Col&#xf3;n GJ, McKechnie JL, et al. . A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med (2020) 26:1070&#x2013;6. doi: 10.1038/s41591-020-0944-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0944-y</ArticleId><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med (2021) 27:28&#x2013;33. doi: 10.1038/s41591-020-01202-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01202-8</ArticleId><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, Dhodapkar RM, Lu P, Gehlhausen JR, et al. . Distinguishing features of Long COVID identified through immune profiling. Nature (2023) 623:139&#x2013;48. doi:&#xa0;10.1038/s41586-023-06651-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC . Long COVID or post-COVID conditions, in: Centers for Disease Control and Prevention (2023). Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html (Accessed October 3, 2023).</Citation></Reference><Reference><Citation>Chen C, Parthasarathy S, Leung JM, Wu MJ, Drake KA, Ridaura VK, et al. . Distinct temporal trajectories and risk factors for Post-acute sequelae of SARS-CoV-2 infection. Front Med (2023) 10:1227883. doi:&#xa0;10.3389/fmed.2023.1227883</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1227883</ArticleId><ArticleId IdType="pmc">PMC10614284</ArticleId><ArticleId IdType="pubmed">37908849</ArticleId></ArticleIdList></Reference><Reference><Citation>
Peikon I, Tong G, Liu D, Chu C. Quantitative massively parallel proteomics (2021). US Patent. Available at: https://patentimages.storage.googleapis.com/c5/ad/a7/d0f4ff04f8712a/US20210132078A1.pdf (Accessed October 2, 2023).</Citation></Reference><Reference><Citation>Drake KA, Talantov D, Tong GJ, Lin JT, Verheijden S, Katz S, et al. . Multi-omic profiling reveals early immunological indicators for identifying COVID-19 Progressors. Clin Immunol (2023) 256:109808. doi: 10.1016/j.clim.2023.109808</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2023.109808</ArticleId><ArticleId IdType="pubmed">37852344</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ebinger JE, Mostafa R, Budde P, Gajewski J, Walker B, et al. . Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. J Transl Med (2021) 19:524. doi: 10.1186/s12967-021-03184-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-03184-8</ArticleId><ArticleId IdType="pmc">PMC8716184</ArticleId><ArticleId IdType="pubmed">34965855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med (2008) 3:17. doi: 10.1186/1751-0473-3-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1751-0473-3-17</ArticleId><ArticleId IdType="pmc">PMC2633005</ArticleId><ArticleId IdType="pubmed">19087314</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 102:15545&#x2013;50. doi: 10.1073/pnas.0506580102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun (2021) 12:6571. doi: 10.1038/s41467-021-26513-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26513-3</ArticleId><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVergne SM, Stromberg S, Baxter BA, Webb TL, Dutt TS, Berry K, et al. . A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae. BMC Infect Dis (2021) 21:677. doi: 10.1186/s12879-021-06359-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06359-2</ArticleId><ArticleId IdType="pmc">PMC8276222</ArticleId><ArticleId IdType="pubmed">34256735</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckers L, Somers V, Fraussen J. IgDCD27 double negative (DN) B cells: Origins and functions in health and disease. Immunol Lett (2023) 255:67&#x2013;76. doi: 10.1016/j.imlet.2023.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2023.03.003</ArticleId><ArticleId IdType="pubmed">36906182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz I, Wei C, Jenks SA, Cashman KS, Tipton C, Woodruff MC, et al. . Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front Immunol (2019) 10:2458. doi: 10.3389/fimmu.2019.02458</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02458</ArticleId><ArticleId IdType="pmc">PMC6813733</ArticleId><ArticleId IdType="pubmed">31681331</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. . Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science (2020) 369:718&#x2013;24. doi: 10.1126/science.abc6027</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, M&#xf8;ller R, et al. . Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell (2020) 181:1036&#x2013;45.e9. doi: 10.1016/j.cell.2020.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, et al. . Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol (2020) 5:eabd1554. doi:&#xa0;10.1126/sciimmunol.abd1554</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd1554</ArticleId><ArticleId IdType="pmc">PMC7402635</ArticleId><ArticleId IdType="pubmed">32651212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. . Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature (2020) 584:463&#x2013;9. doi: 10.1038/s41586-020-2588-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferies CA. Regulating IRFs in IFN driven disease. Front Immunol (2019) 10:325. doi: 10.3389/fimmu.2019.00325</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00325</ArticleId><ArticleId IdType="pmc">PMC6449421</ArticleId><ArticleId IdType="pubmed">30984161</ArticleId></ArticleIdList></Reference><Reference><Citation>DeDiego ML, Nogales A, Martinez-Sobrido L, Topham DJ. Interferon-induced protein 44 interacts with cellular FK506-binding protein 5, negatively regulates host antiviral responses, and supports virus replication. MBio (2019) 10:e01839&#x2013;19. doi:&#xa0;10.1128/mBio.01839-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01839-19</ArticleId><ArticleId IdType="pmc">PMC6712396</ArticleId><ArticleId IdType="pubmed">31455651</ArticleId></ArticleIdList></Reference><Reference><Citation>DeDiego ML, Martinez-Sobrido L, Topham DJ. Novel functions of IFI44L as a feedback regulator of host antiviral responses. J Virol (2019) 93:e01159&#x2013;19. doi:&#xa0;10.1128/JVI.01159-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01159-19</ArticleId><ArticleId IdType="pmc">PMC6803278</ArticleId><ArticleId IdType="pubmed">31434731</ArticleId></ArticleIdList></Reference><Reference><Citation>Basters A, Knobeloch K-P, Fritz G. USP18 - a multifunctional component in the interferon response. Biosci Rep (2018) 38:BSR20180250. doi:&#xa0;10.1042/BSR20180250</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20180250</ArticleId><ArticleId IdType="pmc">PMC6240716</ArticleId><ArticleId IdType="pubmed">30126853</ArticleId></ArticleIdList></Reference><Reference><Citation>Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, et al. . Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 103:5514&#x2013;9. doi: 10.1073/pnas.0509996103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0509996103</ArticleId><ArticleId IdType="pmc">PMC1459386</ArticleId><ArticleId IdType="pubmed">16540544</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol (2020) 20:537&#x2013;51. doi: 10.1038/s41577-020-0288-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0288-3</ArticleId><ArticleId IdType="pmc">PMC7094958</ArticleId><ArticleId IdType="pubmed">32203325</ArticleId></ArticleIdList></Reference><Reference><Citation>Risso A, Smilovich D, Capra MC, Baldissarro I, Yan G, Bargellesi A, et al. . CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression. J Immunol (1991) 146:4105&#x2013;14. doi: 10.4049/jimmunol.146.12.4105</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.146.12.4105</ArticleId><ArticleId IdType="pubmed">1710239</ArticleId></ArticleIdList></Reference><Reference><Citation>Testi R, Phillips JH, Lanier LL. T cell activation via Leu-23 (CD69). J Immunol (1989) 143:1123&#x2013;8. doi: 10.4049/jimmunol.143.4.1123</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.143.4.1123</ArticleId><ArticleId IdType="pubmed">2501389</ArticleId></ArticleIdList></Reference><Reference><Citation>Pignarre A, Chatonnet F, Caron G, Haas M, Desmots F, Fest T. Plasmablasts derive from CD23- activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction. Blood (2021) 137:1166&#x2013;80. doi: 10.1182/blood.2020005083</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020005083</ArticleId><ArticleId IdType="pubmed">33150420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BR, Park SH, Jeong YA, Na YJ, Kim JL, Jo MJ, et al. . RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer. Oncogene (2019) 38:3903&#x2013;18. doi: 10.1038/s41388-019-0693-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-019-0693-x</ArticleId><ArticleId IdType="pubmed">30692634</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsch M, G&#xfc;nther SD, Schwarzer R, Albert M-C, Schorn F, Werthenbach JP, et al. . Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature (2019) 575:683&#x2013;7. doi: 10.1038/s41586-019-1770-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1770-6</ArticleId><ArticleId IdType="pubmed">31748744</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem (2003) 278:28045&#x2013;51. doi: 10.1074/jbc.M300554200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M300554200</ArticleId><ArticleId IdType="pubmed">12732644</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S&#x2018;ichi, et al. . Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 4:11&#x2013;9. doi: 10.1038/ncb714</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb714</ArticleId><ArticleId IdType="pubmed">11780126</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter RS, Nieters A, Kr&#xe4;usslich H-G, Brockmann SO, G&#xf6;pel S, Kindle G, et al. . Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ (2022) 379:e071050. doi: 10.1136/bmj-2022-071050</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-071050</ArticleId><ArticleId IdType="pmc">PMC9557001</ArticleId><ArticleId IdType="pubmed">36229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw Open (2021) 4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly JD, Curteis T, Rawal A, Murton M, Clark LJ, Jafry Z, et al. . SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis. Eur Respir Rev (2023) 32:220254. doi:&#xa0;10.1183/16000617.0254-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0254-2022</ArticleId><ArticleId IdType="pmc">PMC10336551</ArticleId><ArticleId IdType="pubmed">37437914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al. . Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun (2022) 13:446. doi: 10.1038/s41467-021-27797-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson RC, Simons NW, Wilkins L, Cheng E, Del Valle DM, Hoffman GE, et al. . Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. Nat Med (2022) 29:236&#x2013;46. doi:&#xa0;10.1038/s41591-022-02107-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02107-4</ArticleId><ArticleId IdType="pmc">PMC9873574</ArticleId><ArticleId IdType="pubmed">36482101</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol (2021) 12:698169. doi: 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T, et al. . Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science (2020) 369:1210&#x2013;20. doi: 10.1126/science.abc6261</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6261</ArticleId><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, et al. . Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell (2020) 183:1479&#x2013;95.e20. doi: 10.1016/j.cell.2020.10.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.037</ArticleId><ArticleId IdType="pmc">PMC7598382</ArticleId><ArticleId IdType="pubmed">33171100</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L, Mescia F, Turner L, Hanson AL, Kotagiri P, Dunmore BJ, et al. . Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity (2021) 54:1257&#x2013;75.e8. doi: 10.1016/j.immuni.2021.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, et al. . Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol (2020) 11:610300. doi: 10.3389/fimmu.2020.610300</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.610300</ArticleId><ArticleId IdType="pmc">PMC7772470</ArticleId><ArticleId IdType="pubmed">33391280</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (2020) 370:eabd4585. doi:&#xa0;10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. . Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths. Sci Immunol (2021) 6:eabl4340. doi:&#xa0;10.1126/sciimmunol.abl4340</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4340</ArticleId><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. . Diverse functional autoantibodies in patients with COVID-19. Nature (2021) 595:283&#x2013;8. doi: 10.1038/s41586-021-03631-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux J, Dotan A, Fritzler MJ, Bogdanos DP, Meroni PL, Roggenbuck D, et al. . Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev (2022) 21:103012. doi: 10.1016/j.autrev.2021.103012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.103012</ArticleId><ArticleId IdType="pmc">PMC8656211</ArticleId><ArticleId IdType="pubmed">34896650</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagyas M, Nagy B, Jr, R&#xe1;duly AP, M&#xe1;nyin&#xe9; IS, M&#xe1;rtha L, Erd&#x151;si G, et al. . The majority of severe COVID-19 patients develop anti-cardiac autoantibodies. Geroscience (2022) 44:2347&#x2013;60. doi: 10.1007/s11357-022-00649-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-022-00649-6</ArticleId><ArticleId IdType="pmc">PMC9483490</ArticleId><ArticleId IdType="pubmed">36112333</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. . Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): A prospective cohort study. Clin Infect Dis (2022) 74:1191&#x2013;8. doi: 10.1093/cid/ciab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, F&#xfc;rst J, Schulze-Rothe S, Wallukat A, et al. . Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun (2021) 4:100100. doi: 10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohandas S, Jagannathan P, Henrich TJ, Sherif ZA, Bime C, Quinlan E, et al. . Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC). Elife (2023) 12:e86014. doi:&#xa0;10.7554/eLife.86014</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86014</ArticleId><ArticleId IdType="pmc">PMC10219649</ArticleId><ArticleId IdType="pubmed">37233729</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadaw AS, Sahner DK, Sidky H, Afzali B, Hotaling N, Pfaff ER, et al. . Preexisting autoimmunity is associated with increased severity of coronavirus disease 2019: A retrospective cohort study using data from the national COVID cohort collaborative (N3C). Clin Infect Dis (2023) 77:816&#x2013;26. doi: 10.1093/cid/ciad294</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad294</ArticleId><ArticleId IdType="pmc">PMC10506777</ArticleId><ArticleId IdType="pubmed">37207367</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol (2020) 11:617089. doi: 10.3389/fimmu.2020.617089</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.617089</ArticleId><ArticleId IdType="pmc">PMC7873987</ArticleId><ArticleId IdType="pubmed">33584709</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira C, Harris BHL, Di Giovannantonio M, Rosadas C, Short C-E, Quinlan R, et al. . The association between antibody response to severe acute respiratory syndrome Coronavirus 2 infection and post-COVID-19 syndrome in healthcare workers. J Infect Dis (2021) 223:1671&#x2013;6. doi: 10.1093/infdis/jiab120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab120</ArticleId><ArticleId IdType="pmc">PMC7989400</ArticleId><ArticleId IdType="pubmed">33675366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y-M, Shin E-C. Type I and III interferon responses in SARS-CoV-2 infection. Exp Mol Med (2021) 53:750&#x2013;60. doi: 10.1038/s12276-021-00592-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00592-0</ArticleId><ArticleId IdType="pmc">PMC8099704</ArticleId><ArticleId IdType="pubmed">33953323</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M-H, Salloum S, Wang JY, Wong LP, Regan J, Lefteri K, et al. . II, and III interferon signatures correspond to coronavirus disease 2019 severity. J Infect Dis (2021) 224:777&#x2013;82. doi: 10.1093/infdis/jiab288</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab288</ArticleId><ArticleId IdType="pmc">PMC8244575</ArticleId><ArticleId IdType="pubmed">34467988</ArticleId></ArticleIdList></Reference><Reference><Citation>Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. . The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A (2022) 119:e2200413119. doi: 10.1073/pnas.2200413119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2200413119</ArticleId><ArticleId IdType="pmc">PMC9173764</ArticleId><ArticleId IdType="pubmed">35576468</ArticleId></ArticleIdList></Reference><Reference><Citation>Esp&#xed;n E, Yang C, Shannon CP, Assadian S, He D, Tebbutt SJ. Cellular and molecular biomarkers of long COVID: a scoping review. EBioMedicine (2023) 91:104552. doi: 10.1016/j.ebiom.2023.104552</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104552</ArticleId><ArticleId IdType="pmc">PMC10082390</ArticleId><ArticleId IdType="pubmed">37037165</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Ramonell RP, Haddad NS, Anam FA, Rudolph ME, Walker TA, et al. . Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature (2022) 611:139&#x2013;47. doi: 10.1038/s41586-022-05273-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05273-0</ArticleId><ArticleId IdType="pmc">PMC9630115</ArticleId><ArticleId IdType="pubmed">36044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. . Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol (2020) 21:1506&#x2013;16. doi: 10.1038/s41590-020-00814-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00814-z</ArticleId><ArticleId IdType="pmc">PMC7739702</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoehn KB, Ramanathan P, Unterman A, Sumida TS, Asashima H, Hafler DA, et al. . Cutting edge: distinct B cell repertoires characterize patients with mild and severe COVID-19. J Immunol (2021) 206:2785&#x2013;90. doi: 10.4049/jimmunol.2100135</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100135</ArticleId><ArticleId IdType="pmc">PMC8627528</ArticleId><ArticleId IdType="pubmed">34049971</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosa-Hern&#xe1;ndez VA, Torres-Ru&#xed;z J, Cervantes-D&#xed;az R, Romero-Ram&#xed;rez S, P&#xe1;ez-Franco JC, Meza-S&#xe1;nchez DE, et al. . B cell subsets as severity-associated signatures in COVID-19 patients. Front Immunol (2020) 11:611004. doi: 10.3389/fimmu.2020.611004</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.611004</ArticleId><ArticleId IdType="pmc">PMC7744304</ArticleId><ArticleId IdType="pubmed">33343585</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen SCA, Yang F, Jackson KJL, Hoh RA, R&#xf6;ltgen K, Jean GH, et al. . Human B cell clonal expansion and convergent antibody responses to SARS-Cov-2. Cell Host Microbe (2020) 28:516&#x2013;25.e5. doi: 10.1016/j.chom.2020.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.09.002</ArticleId><ArticleId IdType="pmc">PMC7470783</ArticleId><ArticleId IdType="pubmed">32941787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MKY, Gong L, Kwong DL-W, Lee VH-F, Lee AW-M, Guan X-Y, et al. . Functions of double-negative B cells in autoimmune diseases, infections, and cancers. EMBO Mol Med (2023) 15:e17341. doi: 10.15252/emmm.202217341</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202217341</ArticleId><ArticleId IdType="pmc">PMC10493577</ArticleId><ArticleId IdType="pubmed">37272217</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Li Z, Hu F. Double-negative (DN) B cells: an under-recognized effector memory B cell subset in autoimmunity. Clin Exp Immunol (2021) 205:119&#x2013;27. doi: 10.1111/cei.13615</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13615</ArticleId><ArticleId IdType="pmc">PMC8274172</ArticleId><ArticleId IdType="pubmed">33969476</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, Cashman KS, Woodruff MC, Lee FE-H, Sanz I. Extrafollicular responses in humans and SLE. Immunol Rev (2019) 288:136&#x2013;48. doi: 10.1111/imr.12741</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12741</ArticleId><ArticleId IdType="pmc">PMC6422038</ArticleId><ArticleId IdType="pubmed">30874345</ArticleId></ArticleIdList></Reference><Reference><Citation>Castleman MJ, Stumpf MM, Therrien NR, Smith MJ, Lesteberg KE, Palmer BE, et al. . Autoantibodies elicited with SARS-CoV-2 infection are linked to alterations in double negative B cells. Front Immunol (2022) 13:988125. doi: 10.3389/fimmu.2022.988125</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.988125</ArticleId><ArticleId IdType="pmc">PMC9484582</ArticleId><ArticleId IdType="pubmed">36131937</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes RA, Clarke K, Gonzales SJ, Cantwell AM, Garza R, Catano G, et al. . SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease. PLoS ONE (2021) 16(12):e0261656. doi:&#xa0;10.1371/journal.pone.0261656</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261656</ArticleId><ArticleId IdType="pmc">PMC8694470</ArticleId><ArticleId IdType="pubmed">34936684</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliviero B, Varchetta S, Mele D, Mantovani S, Cerino A, Perotti CG, et al. . Expansion of atypical memory B cells is a prominent feature of COVID-19. Cell Mol Immunol (2020) 17:1101&#x2013;3. doi: 10.1038/s41423-020-00542-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00542-2</ArticleId><ArticleId IdType="pmc">PMC7463104</ArticleId><ArticleId IdType="pubmed">32879471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>